Investigator Meeting @ Society of Urologic Oncology (SUO) 2025 Annual Meeting
Friday, December 5, 2025 12:20pm - 1:20pm
Lunch Included
LEGION-100 Phase 2 Trial Enrolling: 3rd Generation Immunotherapy for mCRPC Patients
Join us to learn about a novel combination immunotherapy that could change the treatment landscape of mCRPC.
Sheraton Phoenix Downtown, Ahwatukee A Room
Lunch included, seating is limited
Meeting Overview
Description of program and speakers
Title: LEGION-100 Phase 2 Trial Enrolling – 3rd Generation Immunotherapy for mCRPC Patients
Speaker:Â Gerald Andriole, M.D., Chief Medical Officer, Urology, Syncromune, Inc.
Description: Syncromune Chief Medical Officer, Urology, and LEGION-100 Phase 2 trial proctor, Dr. Andriole will provide in-depth insights into SYNC-T SV-102, a novel third-generation combination intratumoral/locoregional immunotherapy designed to elicit a systemic antitumor response in patients with metastatic castration-resistant prostate cancer (mCRPC).
This session will showcase Phase 1 clinical results demonstrating safety, immune activation, and early signs of efficacy, highlighting how SYNC-T SV-102 is reshaping the therapeutic landscape for advanced prostate cancer.
Largely, the symposium will spotlight the LEGION-100 Phase 2 clinical trial, now actively enrolling patients and recruiting clinical trial sites across the U.S. Dr. Andriole will share insights into the trial’s design, scientific rationale, and the opportunity for institutions to partner in evaluating this cutting-edge immunotherapy.
Key Topics
Immunotherapy in mCRPC
Trials and data to date.
Novel 3rd Generation Immunotherapy
Combination intratumoral / locoregional
SYNC-T Therapy SV-102
Phase 1 data in mCRPC
LEGION-100 Phase 2 Trial for mCRPC
Trial design, rationale, participation.
Speakers
Gerald Andriole, M.D.
Chief Medical Officer, Urology, Syncromune, Inc.
Gerald L. Andriole, Jr., M.D. was most recently  Professor and Director of Urology at Johns Hopkins University in the National Capital Region, retiring in June 2023. Previously, he had been the Royce Distinguished Professor and Chief of Urologic Surgery at Washington University in St. Louis for over 20 years.
Dr. Andriole has significant expertise in prostate cancer screening, prevention and treatment. He was continuously funded by NIH from 1993-2021 and has contributed over 450 peer-reviewed publications (H-index of 112).  He chaired the Prostate Committee of NCI’s PLCO Cancer Screening Trial and led the international REDUCE Prostate Cancer Chemoprevention Trial. He also chaired the Prostate Committee of the Society of Urologic Oncology Clinical Trials Consortium.
Dr. Andriole is an elected member of the American Surgical Association, American Association of Genitourinary Surgeons, and the Clinical Society of Genitourinary Surgeons. He received the Outstanding Achievement Award from the Urologic Oncology Branch of NCI, the Distinguished Clinician Award from Washington University, the Distinguished Alumni Award from Jefferson Medical College and the Williams Award for Prostate Cancer Research Excellence from the American Urologic Association Urology Care Foundation.
Dr. Andriole participated in the 5-year accelerated medical program at Penn State University and Jefferson Medical College, Philadelphia, PA. He trained in surgery at Strong Memorial Hospital, University of Rochester, NY and completed urology residency at Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. He served a fellowship in Urologic Oncology at the National Cancer Institute of NIH in Bethesda, Maryland prior to joining the faculty at Washington University.
Program Details
12:30pm – 1:30pm
12:30pm - 12:45pm
12:45pm - 1:00pm
1:00pm - 1:20pm
1:20pm - 1:30pm
Conference Directions
Ahwatukee A Room
Society of Urologic Oncology (SUO) 2025 Annual Meeting
Ahwatukee A Room
Sheraton Phoenix Downtown
340 N 3rd St
Phoenix, AZ 85004
602 262-2500
